MYM Expands Scope of Global Offices to Include Sales and Distribution of ‘MYM International Brands Inc.’
MYM Nutraceuticals Inc., (CSE:MYM, OTCBB:MYMMF) (“MYM Nutraceuticals” or the “Company”) is pleased to announce that it has expanded the scope of its global offices to include distribution and sales of the newly formed MYM International Brands Inc. MYM recently incorporated MYM International Brands Inc. to focus on the growing global demand for CBD-rich consumer products.
MYM currently has three global offices covering the territories of: Europe, Asia Pacific, and Latin America, focusing on the sale of bulk CBD-rich isolate. They now will be adding MYM International Brands Inc. products to their sales and distribution portfolio.
European office – CBD consumer products are legal in most of Europe. In their recent report, Brightfield Group, a leading market intelligence firm for the legal CBD and cannabis industries, estimates that the European CBD market will boom over the next four years. The market was estimated at $318 million in 2018 and is expected to grow over 400 percent through 2023.
Asia Pacific office – By 2024, the CBD market in China alone is forecasted to be worth US $15 billion, according to Hong Kong-based investment company Regent Pacific Group, citing the beauty and wellness sector as the main driver.
Latin America office – Central and South America have all the key ingredients for CBD growth: land for production, increasingly relaxed laws for trade, people for creation and consumption, and most importantly, political will. MyCBD.org reports legal sales in Latin America are expected to grow from $125 million in 2018 to more than $776 million by 2027.
“We are excited to bring International Brands to the MYM global offices around the world”, said Erick Factor, CEO of MYM International Brands. “We are well on our way to launching lines of unique brands for both humans and pets in a variety of global markets. The demand for CBD-rich consumer products allows our team to create products for a wide variety of categories including food and beverage, pharmaceuticals, cosmetics, and health and wellness”.
About MYM Nutraceuticals Inc.
MYM Nutraceuticals Inc. is an innovative company focused on the global growth of Cannabis and CBD-rich hemp. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the United States under the following symbols: (CSE: MYM) (OTC: MYMMF) (FRA: 0MY) (DEU: 0MY) (MUN: 0MY) (STU: 0MY).
ON BEHALF OF THE BOARD
Howard Steinberg, CEO
MYM Nutraceuticals Inc.
Keep up to date with MYM on our social media channels:
This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. The Company disclaims and does not undertake any intention or obligation to revise or update such statements, except as required by applicable law. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis dated April 24, 2019 (the “MD&A”) and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.
Forward-looking statements may include, without limitation, statements relating to, but not limited to, the estimated market size for CBD rich products in Europe, Asia-Pacific and Latin America, the Company’s or its subsidiary’s ability to manufacture, distribute or launch CBD products and brands in global markets or in a variety of categories, the ability to expand cultivation and distribution initiatives for cannabis and hemp globally or the acquisition of complementary businesses and assets in the technology, nutraceuticals and CBD sectors; the expected demand for CBD-rich products.
This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).